Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Other Accumulated Expenses (2023 - 2025)

Immunome (IMNM) has disclosed Other Accumulated Expenses for 3 consecutive years, with $1.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Accumulated Expenses fell 90.36% year-over-year to $1.7 million, compared with a TTM value of $1.7 million through Sep 2025, down 90.36%, and an annual FY2024 reading of $24.2 million, up 1248.1% over the prior year.
  • Other Accumulated Expenses was $1.7 million for Q3 2025 at Immunome, down from $10.6 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $24.2 million in Q4 2024 and bottomed at $55000.0 in Q1 2024.
  • Average Other Accumulated Expenses over 3 years is $6.5 million, with a median of $1.8 million recorded in 2023.
  • The sharpest move saw Other Accumulated Expenses soared 7159.44% in 2024, then tumbled 90.36% in 2025.
  • Year by year, Other Accumulated Expenses stood at $1.8 million in 2023, then surged by 1248.1% to $24.2 million in 2024, then plummeted by 92.8% to $1.7 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for IMNM at $1.7 million in Q3 2025, $10.6 million in Q2 2025, and $24.2 million in Q4 2024.